FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2896600825> ?p ?o ?g. }

• W2896600825 endingPage "1492" @default.
• W2896600825 startingPage "1480" @default.
• W2896600825 abstract "Previously reported results from the phase 3 CheckMate 067 trial showed a significant improvement in objective responses, progression-free survival, and overall survival with nivolumab plus ipilimumab or nivolumab alone compared with ipilimumab alone in patients with advanced melanoma. The aim of this report is to provide 4-year updated efficacy and safety data from this study.In this phase 3 trial, eligible patients were aged 18 years or older with previously untreated, unresectable, stage III or stage IV melanoma, known BRAFV600 mutation status, and an Eastern Cooperative Oncology Group performance status of 0 or 1. Patients were randomly assigned 1:1:1 to receive intravenous nivolumab 1 mg/kg plus ipilimumab 3 mg/kg every 3 weeks for four doses, followed by nivolumab 3 mg/kg every 2 weeks, or nivolumab 3 mg/kg every 2 weeks plus placebo, or ipilimumab 3 mg/kg every 3 weeks for four doses plus placebo. Randomisation was done via an interactive voice response system with a permuted block schedule (block size of six) and stratification by PD-L1 status, BRAF mutation status, and metastasis stage. The patients, investigators, study site staff, and study funder were masked to the study drug administered. The co-primary endpoints were progression-free survival and overall survival. Efficacy analyses were done on the intention-to-treat population, whereas safety was assessed in all patients who received at least one dose of study drug. The results presented in this report reflect the 4-year update of the ongoing study with a database lock date of May 10, 2018. This study is registered with ClinicalTrials.gov, number NCT01844505.Between July 3, 2013, and March 31, 2014, 945 patients were enrolled and randomly assigned to nivolumab plus ipilimumab (n=314), nivolumab (n=316), or ipilimumab (n=315). Median follow-up was 46·9 months (IQR 10·9-51·8) in the nivolumab plus ipilimumab group, 36·0 months (10·5-51·4) in the nivolumab group, and 18·6 months (7·6-49·5) in the ipilimumab group. At a minimum follow-up of 48 months from the date that the final patient was enrolled and randomised, median overall survival was not reached (95% CI 38·2-not reached) in the nivolumab plus ipilimumab group, 36·9 months (28·3-not reached) in the nivolumab group, and 19·9 months (16·9-24·6) in the ipilimumab group. The hazard ratio for death for the combination versus ipilimumab was 0·54 (95% CI 0·44-0·67; p<0·0001) and for nivolumab versus ipilimumab was 0·65 (0·53-0·79; p<0·0001). Median progression-free survival was 11·5 months (95% CI 8·7-19·3) in the nivolumab plus ipilimumab group, 6·9 months (5·1-10·2) in the nivolumab group, and 2·9 months (2·8-3·2) in the ipilimumab group. The hazard ratio for progression-free survival for the combination versus ipilimumab was 0·42 (95% CI 0·35-0·51; p<0·0001) and for nivolumab versus ipilimumab was 0·53 (0·44-0·64; p<0·0001). Treatment-related grade 3-4 adverse events were reported in 185 (59%) of 313 patients who received nivolumab plus ipilimumab, 70 (22%) of 313 who received nivolumab, and 86 (28%) of 311 who received ipilimumab. The most common treatment-related grade 3 adverse events were diarrhoea in the nivolumab plus ipilimumab group (29 [9%] of 313) and in the nivolumab group (nine [3%] of 313) and colitis in the ipilimumab group (23 [7%] of 311); the most common grade 4 adverse event in all three groups was increased lipase (15 [5%] of 313 in the combination group, ten [3%] of 313 in the nivolumab group, and four [1%] of 311 in the ipilimumab group). Serious adverse events were not analysed for the 4-year follow-up. In total for the study, there were four treatment-related deaths: two in the nivolumab plus ipilimumab group (one cardiomyopathy and one liver necrosis), one in the nivolumab group (neutropenia), and one in the ipilimumab group (colon perforation). No additional treatment-related deaths have occurred since the previous (3-year) analysis.The results of this analysis at 4 years of follow-up show that a durable, sustained survival benefit can be achieved with first-line nivolumab plus ipilimumab or nivolumab alone in patients with advanced melanoma.Bristol-Myers Squibb." @default.
• W2896600825 created "2018-10-26" @default.
• W2896600825 creator A5002655892 @default.
• W2896600825 creator A5011248803 @default.
• W2896600825 creator A5011257308 @default.
• W2896600825 creator A5015975033 @default.
• W2896600825 creator A5017488456 @default.
• W2896600825 creator A5025809703 @default.
• W2896600825 creator A5031591368 @default.
• W2896600825 creator A5034365278 @default.
• W2896600825 creator A5053441903 @default.
• W2896600825 creator A5054656505 @default.
• W2896600825 creator A5056290263 @default.
• W2896600825 creator A5061348179 @default.
• W2896600825 creator A5065240674 @default.
• W2896600825 creator A5068684456 @default.
• W2896600825 creator A5074975947 @default.
• W2896600825 creator A5076054848 @default.
• W2896600825 creator A5083951620 @default.
• W2896600825 creator A5084967339 @default.
• W2896600825 creator A5089297467 @default.
• W2896600825 date "2018-11-01" @default.
• W2896600825 modified "2023-10-18" @default.
• W2896600825 title "Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial" @default.
• W2896600825 cites W2066148089 @default.
• W2896600825 cites W2096322385 @default.
• W2896600825 cites W2123664981 @default.
• W2896600825 cites W2133075384 @default.
• W2896600825 cites W2155104279 @default.
• W2896600825 cites W2166662937 @default.
• W2896600825 cites W2519279652 @default.
• W2896600825 cites W2611270905 @default.
• W2896600825 cites W2740393355 @default.
• W2896600825 cites W2746991247 @default.
• W2896600825 cites W2747107882 @default.
• W2896600825 cites W2753432434 @default.
• W2896600825 cites W2760893760 @default.
• W2896600825 cites W2761314488 @default.
• W2896600825 cites W2807744160 @default.
• W2896600825 cites W2889967774 @default.
• W2896600825 cites W2891287621 @default.
• W2896600825 doi "https://doi.org/10.1016/s1470-2045(18)30700-9" @default.
• W2896600825 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30361170" @default.
• W2896600825 hasPublicationYear "2018" @default.
• W2896600825 type Work @default.
• W2896600825 sameAs 2896600825 @default.
• W2896600825 citedByCount "953" @default.
• W2896600825 countsByYear W28966008252018 @default.
• W2896600825 countsByYear W28966008252019 @default.
• W2896600825 countsByYear W28966008252020 @default.
• W2896600825 countsByYear W28966008252021 @default.
• W2896600825 countsByYear W28966008252022 @default.
• W2896600825 countsByYear W28966008252023 @default.
• W2896600825 crossrefType "journal-article" @default.
• W2896600825 hasAuthorship W2896600825A5002655892 @default.
• W2896600825 hasAuthorship W2896600825A5011248803 @default.
• W2896600825 hasAuthorship W2896600825A5011257308 @default.
• W2896600825 hasAuthorship W2896600825A5015975033 @default.
• W2896600825 hasAuthorship W2896600825A5017488456 @default.
• W2896600825 hasAuthorship W2896600825A5025809703 @default.
• W2896600825 hasAuthorship W2896600825A5031591368 @default.
• W2896600825 hasAuthorship W2896600825A5034365278 @default.
• W2896600825 hasAuthorship W2896600825A5053441903 @default.
• W2896600825 hasAuthorship W2896600825A5054656505 @default.
• W2896600825 hasAuthorship W2896600825A5056290263 @default.
• W2896600825 hasAuthorship W2896600825A5061348179 @default.
• W2896600825 hasAuthorship W2896600825A5065240674 @default.
• W2896600825 hasAuthorship W2896600825A5068684456 @default.
• W2896600825 hasAuthorship W2896600825A5074975947 @default.
• W2896600825 hasAuthorship W2896600825A5076054848 @default.
• W2896600825 hasAuthorship W2896600825A5083951620 @default.
• W2896600825 hasAuthorship W2896600825A5084967339 @default.
• W2896600825 hasAuthorship W2896600825A5089297467 @default.
• W2896600825 hasConcept C121608353 @default.
• W2896600825 hasConcept C126322002 @default.
• W2896600825 hasConcept C142724271 @default.
• W2896600825 hasConcept C143998085 @default.
• W2896600825 hasConcept C168563851 @default.
• W2896600825 hasConcept C204787440 @default.
• W2896600825 hasConcept C27081682 @default.
• W2896600825 hasConcept C2777658100 @default.
• W2896600825 hasConcept C2777701055 @default.
• W2896600825 hasConcept C2780030458 @default.
• W2896600825 hasConcept C2781433595 @default.
• W2896600825 hasConcept C2908647359 @default.
• W2896600825 hasConcept C31760486 @default.
• W2896600825 hasConcept C502942594 @default.
• W2896600825 hasConcept C535046627 @default.
• W2896600825 hasConcept C71924100 @default.
• W2896600825 hasConcept C99454951 @default.
• W2896600825 hasConceptScore W2896600825C121608353 @default.
• W2896600825 hasConceptScore W2896600825C126322002 @default.
• W2896600825 hasConceptScore W2896600825C142724271 @default.
• W2896600825 hasConceptScore W2896600825C143998085 @default.
• W2896600825 hasConceptScore W2896600825C168563851 @default.
• W2896600825 hasConceptScore W2896600825C204787440 @default.
• W2896600825 hasConceptScore W2896600825C27081682 @default.
• W2896600825 hasConceptScore W2896600825C2777658100 @default.

• next